<DOC>
	<DOCNO>NCT00929695</DOCNO>
	<brief_summary>This randomized phase III trial study low-dose prednisone methylprednisolone see well work compare standard-dose prednisone methylprednisolone treat patient newly diagnose acute graft-versus-host disease ( GVHD ) . Glucocorticoids , prednisone methylprednisolone start dose 2 mg/kg/day standard treatment acute graft-versus-host disease cause donor stem cell transplant . It yet know whether low-dose glucocorticoid effective standard-dose glucocorticoid treat acute graft-versus-host-disease</brief_summary>
	<brief_title>Low-Dose Prednisone Methylprednisolone Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease</brief_title>
	<detailed_description>OBJECTIVES : I . To determine whether low start dose prednisone treatment newly diagnose acute GVHD result decrease prednisone exposure without compromise overall survival . II . To estimate magnitude clinical benefit associate reduction prednisone exposure . OUTLINE : Patients randomize 1 2 treatment arm . ARM I ( Low-dose ; prednisone-equivalent dose initiation treatment 0.5 mg/kg/day 1.0 mg/kg/day ; stratify accord initial symptom severity ) : Patients receive low-dose prednisone methylprednisolone twice daily absence disease progression unacceptable toxicity . ARM II ( Standard-dose ; prednisone-equivalent dose initiation treatment 1.0 mg/kg/day 2.0 mg/kg/day ; stratify accord initial symptom severity ) : Patients receive standard-dose prednisone methylprednisolone twice daily absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 year annually thereafter .</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients newly diagnose acute GVHD ( &gt; = grade IIa ) , judgment attend physician , initial treatment systemic glucocorticoid indicate Patient guardian able willing provide inform consent Hallmarks chronic GVHD GVHD donor lymphocyte infusion ( DLI ) Patient unwilling remain Seattle care Fred Hutchinson Cancer Research Center ( FHCRC ) /Seattle Cancer Care Alliance ( SCCA ) day 42 start treatment GVHD Uncontrolled infection underlie comorbidity ( i.e . severe psychiatric illness ) preclude use `` standarddose '' prednisone Recent diagnosis recurrent progressive malignancy precludes use `` standarddose '' prednisone Any prior systemic therapy acute GVHD ( Patients may receive 2 dos lowdose prednisone prior randomization ; lowdose prednisone define 0.5 mg/kg/dose patient present grade IIa GVHD 1 mg/kg/dose present grade IIbIV GVHD ) Enrollment Blood Marrow Transplant Clinical Trials Network ( BMTCTN ) trial 0802</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>